Osimertinib as Neoadjuvant Therapy for Resectable Non-Small Cell Lung Cancer: A Case Series.
Hu Y, Ren S, Yang L, Tong Z, Wang R, Han W, Zeng C, Li J, Xiao P, Wang L, Yu F, Liu W.
Hu Y, et al. Among authors: wang l, wang r.
Front Pharmacol. 2022 Apr 28;13:912153. doi: 10.3389/fphar.2022.912153. eCollection 2022.
Front Pharmacol. 2022.
PMID: 35571073
Free PMC article.